Rank-Based Analysis of Linear Models Using R

It is well-known that Wilcoxon procedures out perform least squares procedures when the data deviate from normality and/or contain outliers. These procedures can be generalized by introducing weights; yielding so-called weighted Wilcoxon (WW) techniques. In this paper we demonstrate how WW-estimates can be calculated using an L1 regression routine. More importantly, we present a collection of functions that can be used to implement a robust analysis of a linear model based on WW-estimates. For instance, estimation, tests of linear hypotheses, residual analyses, and diagnostics to detect differences in fits for various weighting schemes are discussed. We analyze a regression model, designed experiment, and autoregressive time series model for the sake of illustration. We have chosen to implement the suite of functions using the R statistical software package. Because R is freely available and runs on multiple platforms, WW-estimation and associated inference is now universally accessible.

Rank-Based Analysis of Linear Models Using R

It is well-known that Wilcoxon procedures out perform least squares procedures when the data deviate from normality and/or contain outliers. These procedures can be generalized by introducing weights; yielding so-called weighted Wilcoxon (WW) techniques. In this paper we demonstrate how WW-estimates can be calculated using an L1 regression routine. More importantly, we present a collection of functions that can be used to implement a robust analysis of a linear model based on WW-estimates. For instance, estimation, tests of linear hypotheses, residual analyses, and diagnostics to detect differences in fits for various weighting schemes are discussed. We analyze a regression model, designed experiment, and autoregressive time series model for the sake of illustration. We have chosen to implement the suite of functions using the R statistical software package. Because R is freely available and runs on multiple platforms, WW-estimation and associated inference is now universally accessible

Robust General Linear Models and Graphics via a User Interface (Web RGLM)

Rank-based procedures provide superior estimation and testing techniques when the data deviate from normality or contain gross outliers. However, these robust techniques are rarely incorporated in a nonparametric statistics or methods courses due to the lack of computational tools. One reason for this is the existence of certain unavoidable complexities in the numerical methods due to the absence of a closedform solution for the rank estimation problem. This article introduces a user interface, Web RGLM, which may be used to perform rank-based analyses of linear models across the World Wide Web. These models include simple location problems to complicated ANOVA and ANCOVA designs with multiple comparison procedures. The robust and least squares analyses are presented side-by-side for immediate comparisons. Web RGLM meets many of the computational demands of the classroom as well as the computational demands of quantitative researchers. Several illustrative examples are provided

Time-Series Intervention Analysis Using ITSACORR: Fatal Flaws

The ITSACORR method (Crosbie, 1993, 1995) is evaluated for the analysis of two-phase interrupted time-series designs. It is shown that each component of the ITSACORR framework (including the structural model, the design matrix, the autocorrelation estimator, the ultimate parameter estimation scheme, and the inferential method) contains fatal flaws

Maternal characteristics associated with the dietary intake of nitrates, nitrites, and nitrosamines in women of child-bearing age: a cross-sectional study

<p>Abstract</p> <p>Background</p> <p>Multiple <it>N</it>-nitroso compounds have been observed in animal studies to be both mutagenic and teratogenic. Human exposure to <it>N</it>-nitroso compounds and their precursors, nitrates and nitrites, can occur through exogenous sources, such as diet, drinking water, occupation, or environmental exposures, and through endogenous exposures resulting from the formation of <it>N</it>-nitroso compounds in the body. Very little information is available on intake of nitrates, nitrites, and nitrosamines and factors related to increased consumption of these compounds.</p> <p>Methods</p> <p>Using survey and dietary intake information from control women (with deliveries of live births without major congenital malformations during 1997-2004) who participated in the National Birth Defects Prevention Study (NBDPS), we examined the relation between various maternal characteristics and intake of nitrates, nitrites, and nitrosamines from dietary sources. Estimated intake of these compounds was obtained from the Willet Food Frequency Questionnaire as adapted for the NBDPS. Multinomial logistic regression models were used to estimate odds ratios and 95% confidence intervals for the consumption of these compounds by self-reported race/ethnicity and other maternal characteristics.</p> <p>Results</p> <p>Median intake per day for nitrates, nitrites, total nitrites (nitrites + 5% nitrates), and nitrosamines was estimated at 40.48 mg, 1.53 mg, 3.69 mg, and 0.472 μg respectively. With the lowest quartile of intake as the referent category and controlling for daily caloric intake, factors predicting intake of these compounds included maternal race/ethnicity, education, body mass index, household income, area of residence, folate intake, and percent of daily calories from dietary fat. Non-Hispanic White participants were less likely to consume nitrates, nitrites, and total nitrites per day, but more likely to consume dietary nitrosamines than other participants that participated in the NBDPS. Primary food sources of these compounds also varied by maternal race/ethnicity.</p> <p>Conclusions</p> <p>Results of this study indicate that intake of nitrates, nitrites, and nitrosamines vary considerably by race/ethnicity, education, body mass index, and other characteristics. Further research is needed regarding how consumption of foods high in nitrosamines and <it>N</it>-nitroso precursors might relate to risk of adverse pregnancy outcomes and chronic diseases.</p

Where you look matters for body perception: Preferred gaze location contributes to the body inversion effect

The Body Inversion Effect (BIE; reduced visual discrimination performance for inverted compared to upright bodies) suggests that bodies are visually processed configurally; however, the specific importance of head posture information in the BIE has been indicated in reports of BIE reduction for whole bodies with fixed head position and for headless bodies. Through measurement of gaze patterns and investigation of the causal relation of fixation location to visual body discrimination performance, the present study reveals joint contributions of feature and configuration processing to visual body discrimination. Participants predominantly gazed at the (body-centric) upper body for upright bodies and the lower body for inverted bodies in the context of an experimental paradigm directly comparable to that of prior studies of the BIE. Subsequent manipulation of fixation location indicates that these preferential gaze locations causally contributed to the BIE for whole bodies largely due to the informative nature of gazing at or near the head. Also, a BIE was detected for both whole and headless bodies even when fixation location on the body was held constant, indicating a role of configural processing in body discrimination, though inclusion of the head posture information was still highly discriminative in the context of such processing. Interestingly, the impact of configuration (upright and inverted) to the BIE appears greater than that of differential preferred gaze locations

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

Background Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-positive ductal carcinoma in situ (DCIS). Here, we compare the efficacy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS. Methods In a double-blind, multicentre, randomised placebo-controlled trial, we recruited women who had been diagnosed with locally excised, hormone-receptor-positive DCIS. Eligible women were randomly assigned in a 1:1 ratio by central computer allocation to receive 1 mg oral anastrozole or 20 mg oral tamoxifen every day for 5 years. Randomisation was stratified by major centre or hub and was done in blocks (six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation and only the trial statistician had access to treatment allocation. The primary endpoint was all recurrence, including recurrent DCIS and new contralateral tumours. All analyses were done on a modified intention-to-treat basis (in all women who were randomised and did not revoke consent for their data to be included) and proportional hazard models were used to compute hazard ratios and corresponding confidence intervals. This trial is registered at the ISRCTN registry, number ISRCTN37546358. Results Between March 3, 2003, and Feb 8, 2012, we enrolled 2980 postmenopausal women from 236 centres in 14 countries and randomly assigned them to receive anastrozole (1449 analysed) or tamoxifen (1489 analysed). Median follow-up was 7·2 years (IQR 5·6–8·9), and 144 breast cancer recurrences were recorded. We noted no statistically significant difference in overall recurrence (67 recurrences for anastrozole vs 77 for tamoxifen; HR 0·89 [95% CI 0·64–1·23]). The non-inferiority of anastrozole was established (upper 95% CI <1·25), but its superiority to tamoxifen was not (p=0·49). A total of 69 deaths were recorded (33 for anastrozole vs 36 for tamoxifen; HR 0·93 [95% CI 0·58–1·50], p=0·78), and no specific cause was more common in one group than the other. The number of women reporting any adverse event was similar between anastrozole (1323 women, 91%) and tamoxifen (1379 women, 93%); the side-effect profiles of the two drugs differed, with more fractures, musculoskeletal events, hypercholesterolaemia, and strokes with anastrozole and more muscle spasm, gynaecological cancers and symptoms, vasomotor symptoms, and deep vein thromboses with tamoxifen. Conclusions No clear efficacy differences were seen between the two treatments. Anastrozole offers another treatment option for postmenopausal women with hormone-receptor-positive DCIS, which may be be more appropriate for some women with contraindications for tamoxifen. Longer follow-up will be necessary to fully evaluate treatment differences